(VIANEWS) – ONEOK (OKE), Fidus Investment Corporation (FDUS), Medpace Holdings (MEDP) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. ONEOK (OKE)
26.5% sales growth and 23.14% return on equity
ONEOK, Inc. engages in gathering, processing, fractionation, storage, transportation, and marketing of natural gas and natural gas liquids (NGL) in the United States. It operates through four segments: Natural Gas Gathering and Processing, Natural Gas Liquids, Natural Gas Pipelines, and Refined Products and Crude. The company owns natural gas gathering pipelines and processing plants in the Mid-Continent and Rocky Mountain regions; and provides midstream services to producers of NGLs. It also owns NGL gathering and distribution pipelines in Oklahoma, Kansas, Texas, New Mexico, Montana, North Dakota, Wyoming, and Colorado; terminal and storage facilities in Kansas, Nebraska, Iowa, and Illinois; NGL distribution pipelines in Kansas, Nebraska, Iowa, Illinois, and Indiana; transports refined petroleum products, including unleaded gasoline and diesel; and owns and operates truck- and rail-loading, and -unloading facilities connected to NGL fractionation, storage, and pipeline assets. In addition, the company transports and stores natural gas through regulated interstate and intrastate natural gas transmission pipelines, and natural gas storage facilities. Further, it owns and operates a parking garage in downtown Tulsa, Oklahoma; and leases excess office space and rail cars. Additionally, the company transports, stores, and distributes refined products, NGLs, and crude oil, as well as conducts commodity-related activities, including liquids blending and marketing activities. It serves integrated and independent exploration and production companies; other NGL and natural gas gathering and processing companies; crude oil and natural gas production companies; utilities; industrial companies; natural gasoline distributors; propane distributors; municipalities; ethanol producers; petrochemical, refining, and marketing companies; and heating fuel users, refineries, and exporters. ONEOK, Inc. was founded in 1906 and is headquartered in Tulsa, Oklahoma.
Earnings Per Share
As for profitability, ONEOK has a trailing twelve months EPS of $5.48.
PE Ratio
ONEOK has a trailing twelve months price to earnings ratio of 14.16. Meaning, the purchaser of the share is investing $14.16 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.14%.
Sales Growth
ONEOK’s sales growth is 16.7% for the current quarter and 26.5% for the next.
Volume
Today’s last reported volume for ONEOK is 2180540 which is 39.76% below its average volume of 3619770.
2. Fidus Investment Corporation (FDUS)
19.2% sales growth and 14.42% return on equity
Fidus Investment Corporation is a business development company. It specializing in leveraged buyouts, refinancings, change of ownership transactions, recapitalizations, strategic acquisitions, mezzanine, growth capital, business expansion, lower middle market investments, debt investments, subordinated and second lien loans, senior secured and unitranche debt, preferred equity, warrants, subordinated debt, senior subordinated notes, junior secured loans, and unitranche loans. It does not invest in turnarounds or distressed situations. The fund prefers to invest in aerospace and defense, business services, consumer products and services including retail, food, and beverage, healthcare products and services, industrial products and services, information technology services, niche manufacturing, transportation and logistics, and value-added distribution sectors. It seeks to invest in companies based in United States. The fund typically invests between $5 million and $15 million per transaction in companies with annual revenues between $10 million and $150 million and an annual EBITDA between $3 million and $20 million, but it can occasionally invest in larger or smaller companies. It seeks to acquire minority equity stakes and board observation rights in conjunction with its investments.
Earnings Per Share
As for profitability, Fidus Investment Corporation has a trailing twelve months EPS of $2.91.
PE Ratio
Fidus Investment Corporation has a trailing twelve months price to earnings ratio of 6.67. Meaning, the purchaser of the share is investing $6.67 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.42%.
3. Medpace Holdings (MEDP)
16.1% sales growth and 59.83% return on equity
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Earnings Per Share
As for profitability, Medpace Holdings has a trailing twelve months EPS of $8.88.
PE Ratio
Medpace Holdings has a trailing twelve months price to earnings ratio of 45.23. Meaning, the purchaser of the share is investing $45.23 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 59.83%.
Moving Average
Medpace Holdings’s value is way higher than its 50-day moving average of $314.48 and way higher than its 200-day moving average of $264.29.
4. Fabrinet Ordinary Shares (FN)
13.8% sales growth and 16.98% return on equity
Fabrinet provides optical packaging and precision optical, electro-mechanical, and electronic manufacturing services in North America, the Asia-Pacific, and Europe. The company offers a range of advanced optical and electro-mechanical capabilities in the manufacturing process, including process design and engineering, supply chain management, manufacturing, printed circuit board assembly, advanced packaging, integration, final assembly, and testing. Its products include switching products, including reconfigurable optical add-drop multiplexers, optical amplifiers, modulators, and other optical components and modules that enable network managers to route voice, video, and data communications traffic through fiber optic cables at various wavelengths, speeds, and over various distances. The company's products also comprise tunable lasers, transceivers, and transponders; and active optical cables, which provide high-speed interconnect capabilities for data centers and computing clusters, as well as Infiniband, Ethernet, fiber channel, and optical backplane connectivity. In addition, it provides solid state, diode-pumped, gas, and fiber lasers used in semiconductor processing, biotechnology and medical device, metrology, and material processing industries; and differential pressure, micro-gyro, fuel, and other sensors used in automobiles, as well as non-contact temperature measurement sensors for the medical industry. Further, the company designs and fabricates application-specific crystals, lenses, prisms, mirrors, laser components, and substrates; and other custom and standard borosilicate, clear fused quartz, and synthetic fused silica glass products. It serves original equipment manufacturers of optical communication components, modules and sub-systems, industrial lasers, automotive components, medical devices, and sensors. The company was incorporated in 1999 and is based in George Town, the Cayman Islands.
Earnings Per Share
As for profitability, Fabrinet Ordinary Shares has a trailing twelve months EPS of $6.93.
PE Ratio
Fabrinet Ordinary Shares has a trailing twelve months price to earnings ratio of 29.43. Meaning, the purchaser of the share is investing $29.43 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.98%.
5. STAAR Surgical Company (STAA)
13.4% sales growth and 5.57% return on equity
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Earnings Per Share
As for profitability, STAAR Surgical Company has a trailing twelve months EPS of $0.38.
PE Ratio
STAAR Surgical Company has a trailing twelve months price to earnings ratio of 81.18. Meaning, the purchaser of the share is investing $81.18 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.57%.
6. Jazz Pharmaceuticals plc (JAZZ)
6.8% sales growth and 12.16% return on equity
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy and idiopathic hypersomnia (IH); Xyrem, a sodium oxybate oral solution for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, a cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. The company's lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer; Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase; Vyxeos, a liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. It has licensing and collaboration agreements with Zymeworks Inc.; Sumitomo Pharma Co., Ltd; Werewolf Therapeutics, Inc.; Codiak BioSciences, Inc.; Ligand Pharmaceuticals Incorporated; XL-protein GmbH; and Redx Pharma plc. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
Earnings Per Share
As for profitability, Jazz Pharmaceuticals plc has a trailing twelve months EPS of $6.1.
PE Ratio
Jazz Pharmaceuticals plc has a trailing twelve months price to earnings ratio of 19.21. Meaning, the purchaser of the share is investing $19.21 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.16%.
Volume
Today’s last reported volume for Jazz Pharmaceuticals plc is 724261 which is 18.92% above its average volume of 609013.
Sales Growth
Jazz Pharmaceuticals plc’s sales growth is 7.6% for the ongoing quarter and 6.8% for the next.
7. Eldorado Gold Corporation Ordinary Shares (EGO)
6.4% sales growth and 3.15% return on equity
Eldorado Gold Corporation and its subsidiaries engage in the exploration, discovery, acquisition, financing, development, production, sale, and reclamation of mineral products, primarily in Turkey, Canada, Greece, Brazil, and Romania. The company primarily produces gold, as well as silver, lead, zinc, and iron ore. It operates five mines: Kisladag and Efemcukuru located in western Turkey, Lamaque in Canada, and Olympias and Stratoni located in northern Greece. The company was formerly known as Eldorado Corporation Ltd. and changed its name to Eldorado Gold Corporation in April 1996. Eldorado Gold Corporation was founded in 1992 and is headquartered in Vancouver, Canada.
Earnings Per Share
As for profitability, Eldorado Gold Corporation Ordinary Shares has a trailing twelve months EPS of $0.54.
PE Ratio
Eldorado Gold Corporation Ordinary Shares has a trailing twelve months price to earnings ratio of 18.75. Meaning, the purchaser of the share is investing $18.75 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.15%.
Moving Average
Eldorado Gold Corporation Ordinary Shares’s value is way under its 50-day moving average of $12.18 and under its 200-day moving average of $10.71.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Eldorado Gold Corporation Ordinary Shares’s EBITDA is 16.72.
8. Telefonica Brasil, S.A. ADS (VIV)
6.2% sales growth and 7.3% return on equity
Telefônica Brasil S.A., together with its subsidiaries, operates as a mobile telecommunications company in Brazil. Its fixed line services portfolio includes local, domestic long-distance, and international long-distance calls; and mobile portfolio comprises voice and broadband internet access through 3G, 4G, 4.5G, and 5G, as well as mobile value-added and wireless roaming services. The company also offers data services, including broadband and mobile data services. In addition, it provides pay TV services through IPTV technologies; network services, such as rental of facilities; other services comprising internet access, private network connectivity, computer equipment leasing, extended service, caller identification, voice mail, cellular blocker, and others; wholesale services, including interconnection services to users of other network providers; and digital services, such as entertainment, cloud, and security and financial services. Further, the company offers multimedia communication services, which include audio, data, voice and other sounds, images, texts, and other information, as well as sells devices, such as smartphones, broadband USB modems, and other devices. Additionally, it provides telecommunications solutions and IT support to various industries, such as retail, manufacturing, services, financial institutions, government, etc. It markets and sells its solutions through own stores, dealers, retail and distribution channels, door-to-door sales, and outbound tele sales. The company was formerly known as Telecomunicações de São Paulo S.A. – TELESP and changed its name to Telefônica Brasil S.A. in October 2011. The company was incorporated in 1998 and is headquartered in São Paulo, Brazil.
Earnings Per Share
As for profitability, Telefonica Brasil, S.A. ADS has a trailing twelve months EPS of $0.61.
PE Ratio
Telefonica Brasil, S.A. ADS has a trailing twelve months price to earnings ratio of 17.8. Meaning, the purchaser of the share is investing $17.8 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.3%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Dec 27, 2023, the estimated forward annual dividend rate is 0.59 and the estimated forward annual dividend yield is 5.42%.
